NEW TOP MANAGEMENT
Andrew N. Liveris becomes chief executive officer of Dow; Cambrex appoints John R. Leone as its CEO.

DRUG TEST DISCLOSURE
Lilly will publish results of all its clinical drug trials on its website.

SPIDER VENOM
New analytical approach reveals overlooked class of sulfated nucleosides.

GLOBAL TRADE TALKS
Compromise would cut tariffs on manufactured goods and phase out agricultural export subsidies.

ALZHEIMER'S THERAPY
Antibody treatment clears both plaques and tangles in brains of diseased mice.

PESTICIDE RULES
EPA no longer must consult wildlife agencies about potential effects on endangered species.

BUSH RESPONDS TO 9/11 REPORT
President calls for national intelligence director and new counterterrorism center.

BIOPHARMACEUTICALS
Dow opts out of mammalian cell culture biomanufacturing.

ALTERNATIVE TIMBER
Wood/plastic composites and new wood treatments compete for a share of the lumber market.

WOMEN IN INDUSTRY
Annual C&EN survey reveals a decline in the number of women in top management.

SYNGENTA LAWSUIT
Firm accuses two Chinese companies of illegally producing and selling its insecticide.

PAUL BURG
C&EN talks with Spectrum Chemicals founder and chairman, who created a sizable player in lab chemicals.

"THE RADIOACTIVE BOY SCOUT"
Nonfiction account of a teenager's attempt to make a nuclear reactor is a fascinating read.

COMMENT
HAPPY BIRTHDAY PRF! AND HAPPY ANNIVERSARY, TOO!

The Lighter Side Of C&EN

PEOPLE

MEETINGS

NEWSCRIPTS